Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults ...Middle East

-- Additional data from RSV re-vaccination trial demonstrates trend of approximately 60-80% higher RSV neutralizing antibodies (nAbs) for Clover's RSV vaccine compared head-to-head versus AREXVY (GSK) in older adults who previously received an initial dose of AREXVY -- -- Re-vaccination...

Hence then, the article about clover announces additional positive u s phase i clinical data for rsv re vaccination in older adults was published today ( Wednesday 25/03/2026 - 02:53 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Clover Announces Additional Positive U.S. Phase I Clinical Data for RSV Re-Vaccination in Older Adults )

Also on site :

• War in Iran Is Disrupting Air Travel, Hitting Middle East Hardest
• HBO Max Developing Pair Of Euro Medical Dramas & Taking Creative Cues From ‘The Pitt’
• German military satellite plan alarms EU – Reuters